Your Messages Inbox
Your Article Summary
See Latest ArticlesSPIRIT IV Results Reaffirm Strong Performance of Boston Scientific PROMUS and TAXUS Express Stents
Boston Scientific, 09/24/09
Boston Scientific Corporation welcomed one–year data from the SPIRIT IV clinical trial comparing the XIENCE V Everolimus–Eluting Coronary Stent System to the TAXUS Express2™ Paclitaxel–Eluting Coronary Stent System. The results support the benefits of paclitaxel–eluting stents in diabetic patients. The trial enrolled 3,690 patients, including 1,140 diabetics, the largest diabetic subset ever studied in a drug–eluting stent clinical trial.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid
Journal of Clinical Microbiology, 12/03/09
Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09
Article Search
Sponsor